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Abstract
Background: The purpose of this study was to determine the orthotic and therapeutic effects of daily community
applied FES to the ankle dorsiflexors in a randomized controlled trial. We hypothesized that children receiving the
eight-week FES treatment would demonstrate orthotic and therapeutic effects in gait and spasticity as well as better
community mobility and balance skills compared to controls not receiving FES.
Methods: This randomized controlled trial involved 32 children (mean age 10 yrs 3 mo, SD 3 yrs 3 mo; 15 females, 17
males) with unilateral spastic cerebral palsy and a Gross Motor Function Classification System of I or II randomly assigned
to a FES treatment group (n = 16) or control group (n = 16). The treatment group received eight weeks of daily FES
(four hours per day, six days per week) and the control group received usual orthotic and therapy treatment. Children
were assessed at baseline, post FES treatment (eight weeks) and follow-up (six weeks after post FES treatment). Outcome
measures included lower limb gait mechanics, clinical measures of gastrocnemius spasticity and community mobility
balance skills.
Results: Participants used the FES for a mean daily use of 6.2 (SD 3.2) hours over the eight-week intervention period. With
FES, the treatment group demonstrated a significant (p < 0.05) increase in initial contact ankle angle (mean difference
11.9° 95 % CI 6.8° to 17.1°), maximum dorsiflexion ankle angle in swing (mean difference 8.1° 95 % CI 1.8° to 14.4°)
normalized time in stance (mean difference 0.27 95 % CI 0.05 to 0.49) and normalized step length (mean difference 0.06
95 % CI 0.003 to 0.126) post treatment compared to the control group. Without FES, the treatment group significantly
increased community mobility balance scores at post treatment (mean difference 8.3 units 95 % CI 3.2 to 13.4 units) and
at follow-up (mean difference 8.9 units 95 % CI 3.8 to13.9 units) compared to the control group. The treatment group
also had significantly reduced gastrocnemius spasticity at post treatment (p = 0.038) and at follow-up (dynamic range of
motion mean difference 6.9°, 95 % CI 0.4° to 13.6°; p = 0.035) compared to the control group.
Conclusion: This study documents an orthotic effect with improvement in lower limb mechanics during gait.
Therapeutic effects i.e. without FES were observed in clinical measures of gastrocnemius spasticity, community mobility
and balance skills in the treatment group at post treatment and follow-up. This study supports the use of FES applied
during daily walking activities to improve gait mechanics as well as to address community mobility issues among
children with unilateral spastic cerebral palsy.
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Background
Cerebral palsy (CP) refers to a group of permanent motor
dysfunctions due to non-progressive damage to the devel-
oping brain [1]. Unilateral spastic cerebral palsy (USCP) is
the most common presentation of CP and children are typ-
ically classified as having a Gross Motor Function Classifi-
cation System (GMFCS) and Winters Gage and Hicks gait
classification of I or II [2–4]. This means that despite
impairments such as spasticity and muscle contracture par-
ticularly at the ankle joint, children remain functionally
ambulant. Equinus during gait is a common problem
alongside functional issues with balance and commu-
nity mobility [3, 4].
The neuronal group selection theory provides an es-
sential framework to understanding the balance and
community mobility limitations in children with USCP
[5]. Based on this framework, children with USCP display
primary repertoires of movement that enable functional
mobility. However, the combination of impairments usu-
ally present in children with USCP may limit the develop-
ment of secondary repertoires of movement that are
essential for movement adaptability [6]. This deficit in
movement adaptability restricts activity such as commu-
nity mobility and balance skills, and may even increase
their risk of falls during gait. The expansion of primary
and secondary repertoires requires the implementation of
the principles of motor learning. Principles of motor
learning require treatments to be activity based or task
specific that is frequently repeated and challenged in
contextually relevant environments [7–9].
Current treatments to improve the gait of children with
USCP include pharmacological strategies such as botu-
linum toxin type A, implemented alongside a range of
physiotherapy treatments and/or the prescription of ankle
foot orthoses (AFOs) [10]. Although AFOs improve ankle
kinematics and temporal-spatial parameters during gait
[11, 12], for high functioning children, the external sup-
port of an AFO may hinder balance strategies for sec-
ondary repertoire expansion as well as impede power
generation for effective push off during walking and
running [11–13]. Evidence supporting the use of AFOs
is mainly focused on the effect it has on body structure
and function. It is currently unclear what effect AFOs
have with long term use as well as the effect it has on
activity and participation [7, 14, 15]. Thus investigation
into alternate interventions is warranted.
Functional Electrical Stimulation (FES) has the po-
tential to meet the motor learning needs to expand
movement repertoires because it can be implemented
frequently during functional tasks such as walking.
Muscles are artificially stimulated using an electrical
current that is transmitted through electrodes placed
over the surface of the skin above the target muscle
and nerve [16]. When FES is applied to the ankle
dorsiflexors during gait it can act as an orthosis by
initiating a muscle contraction to dorsiflex the ankle
joint, thus allowing for improved toe clearance dur-
ing the swing phase of gait (known as the orthotic
effect) [17, 18].
In a recent systematic review, the use of lower limb
muscle electrical stimulation for improving gait and
functional activity was cautiously advocated for children
with CP [19]. However included in this review were
studies where electrical stimulation was not functionally
applied, hence given the overwhelming evidence sup-
porting the need for specificity of treatment, the limited
effect on gait and activity is understandable [7, 20, 21].
Since this review, research has emerged with FES applied
to the ankle dorsiflexors during the swing phase of gait,
and though not randomized controlled trials, results
have supported an orthotic effect with improvements in
ankle kinematics enabling toe clearance [17, 22, 23]. De-
termining whether the effects last beyond the treatment
period with the removal of FES (known as the thera-
peutic effect) and whether it improves community mo-
bility and balance skills has not yet been determined and
so has been a recommendation for future research in
this area [19].
This study aimed to determine the orthotic and thera-
peutic effects of daily community applied FES to the
ankle dorsiflexors in a randomized controlled trial. We
hypothesized that children who received the eight-week
FES treatment would demonstrate an orthotic effect
with improved lower limb kinematics (i.e. elevated dorsi-
flexion during the swing phase of gait) during the gait
cycle compared to controls not receiving FES. Secondly,
after the removal of FES, children who were in the FES
treatment group would demonstrate a therapeutic effect
with improved lower limb kinematics during gait, better
community mobility and balance scores and reduced
gastrocnemius spasticity compared to controls that did
not receive FES.
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Methods
Study design
The study design was a randomized controlled trial of
daily community applied FES to the ankle dorsiflexors in
gait compared with usual care (control group).
Participants
Participants were referred to the study by Physiotherapists
and Paediatric Rehabilitation Consultants. Participant in-
clusion criteria are detailed in Table 1. Participants who
had underwent botulinum toxin type A were included, but
scheduled to commence the study at three months post
injections [24]. Study recruitment took place between June
and July 2013 from clinics of the Cerebral Palsy Mobility
Service at Princess Margaret Hospital for Children and
The Centre for Cerebral Palsy, Perth Australia with the
final assessments completed by April 2014. Human eth-
ics approval was obtained from the Human Research
Ethics Committees of Princess Margaret Hospital, Perth
Australia and The University of Western Australia, Perth
Australia. The committee’s recommendations were ad-
hered to and written and informed consent for participa-
tion and publication was obtained.
Procedure
An initial appointment with the principal investigator
(DP) was scheduled to determine FES tolerance and
study protocol. Randomization to either the FES or con-
trol group was achieved through a coin toss, by an indi-
vidual uninvolved with the study. Randomization only
occurred once two matched participants were enrolled.
Matched participants were of the same GMFCS level,
and were within two years of age for children aged be-
tween five and 10, and within six years for children aged
between 11 and 18. This method was applied to improve
the homogeneity of each group in terms of age and gross
motor function.
Participants were asked not to participate in any new
sporting activities during the study and to maintain pre-
existing therapy throughout the 14-week study period so
that the effects of FES treatment could be determined.
The Actigraph® (GT3X, ActiGraph, Penascola, Florida,
USA), a triaxial device was used to monitor time spent
in moderate to vigorous physical activity (MVPA) [25]
because of its potential to confound the overall outcome
from FES intervention.
Outcome measures were assessed at baseline, post-
treatment (following eight weeks of FES intervention)
and follow-up (six weeks after the post-treatment). The
presence of an orthotic effect was determined in the
between group comparison at post treatment, whilst
the treatment group was wearing the FES device during
the gait analysis assessment. A therapeutic effect was de-
termined both at post treatment and at follow-up through
the examination of between group differences for the
community mobility balance measures, spasticity mea-
sures, as well as in the gait analysis, but only when the
treatment group was not wearing the FES device.
Outcome measures
This randomized controlled trial of daily community
FES assessed outcomes across all domains of the Inter-
national Classification of Functioning Child and Youth
Version. This paper focuses on the results pertaining to
the effects of FES on the domains of body structure and
function and activity. The primary outcomes were lower
limb biomechanics and included ankle kinematics and
temporal spatial measures during walking gait cycle and
community balance and mobility estimates. The second-
ary measures were clinical assessments of gastrocnemius
spasticity. As this study was conducted within the frame-
work of current clinical care, measures of passive dorsi-
flexion with the knee extended and popliteal angles were
also taken at all assessment time points to ensure no
detrimental loss of range of motion over the 14 weeks
study period. This was considered to be important par-
ticularly in the absence of AFOs. Though this was not
an outcome measure, the results may be of interest to
clinicians and so are presented as Additional file 1 in
this paper.
Gait analysis
Two dimensional gait assessment was conducted at
The School of Sport Science, Exercise and Health Gait
Laboratory at The University of Western Australia.
Three Bonita™ cameras (Vicon© Motion Systems Ltd UK)
capturing at 100Hz for sagittal (left and right) and coronal
(one camera) views were positioned and synchronized to
capture video with two AMTI force platforms (1,000Hz).
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Passive dorsiflexion range of
affected ankle of at least 5°
• History of uncontrolled seizure
disorder
• Full passive knee extension
bilaterally
• Orthopaedic lower limb surgery
on the affected side in the past
12 months
• Dynamic popliteal angle of
no more than 45°
• Orthopaedic metal ware at the
site of electrical stimulation
• Able to cooperate with
assessment procedures
• Botulinum toxin in lower limb
in the past 3 months
• Willing to use the Walk Aide®
at least 4 hours a day, 6 days
a week for 8 weeks
• GMFCS I or II, unilateral spastic
cerebral palsy
(with or without dystonia)
• Aged between 5 and 18
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Children were asked to walk at a self- selected walking
speed along a 10 m walkway to capture five successful trials
i.e. uninterrupted foot strike on force platform. Bright
coloured, round stickers were placed on bilateral greater
trochanters, anterior superior iliac spine, posterior superior
iliac spine, acromion clavicular joint, medial and lateral
femoral epicondyles, patella, medial malleoli, lateral malle-
oli, head of the fifth metatarsal and calcaneus. This allowed
identification of specific anatomical landmarks and joint
centers during video motion capture. SiliconCoach Pro7 ®
(Siliconcoach Ltd, Dunedin, New Zealand), was used for
video analysis with initial contact and toe-off identified
from the vertical ground reaction force measure from the
platforms (>10 N and <10 N respectively). Ankle angle was
calculated between the tibia and the foot from the sagittal
plane high-speed video (using the markers on the lateral
femoral epicondyles, lateral malleoli and head of the fifth
metatarsal). Ankle dorsi/plantarflexion angles were calcu-
lated at four discrete time points, 1) initial foot contact, 2)
maximum dorsiflexion in stance, 3) toe off and 4) max-
imum dorsiflexion in swing. Temporal-spatial measures in-
cluded time in stance, step length normalized to height
[26], velocity prior to initial foot contact and walking
velocity over 5 m. Participants were assessed walking in
shoes and in-shoe orthoses (if any) at all assessment time
points. Participants in the FES treatment group were
assessed both with (to determine the orthotic effect)
and without (to determine the therapeutic effect) the
FES device at post-treatment. It was not possible to
blind the assessor regarding group and time point allo-
cation due to the facial identity and Walk Aide® visibil-
ity on the video.
Clinical tests
The clinical tests were performed at Princess Margaret
Hospital for Children by an experienced physiotherapist
(DP) and research assistant, following the outlined pro-
tocols at all of the time points. It was not possible to
blind the assessors to group or assessment time point
allocation.
Community mobility and balance skills
The Community Balance and Mobility Scale (CBMS) is
a valid and reliable clinical tool that rates performance
quality (out of a possible 96 points) of high level commu-
nity balance and mobility skills in ambulatory patients
with neurological impairment [27–29]. It includes items
relevant for everyday community mobility such as turning,
step-ups, walking and looking, direction changes and pick-
ing things up off the ground when walking. The CBMS
was chosen because it would not have a ceiling effect for
children with a GMFCS level of 1 as used previously by
Brien and Sveistrup 2011 [28]. An overall change in score
by five points is considered clinically meaningful,
reflecting true change in confidence in community mobil-
ity and community integration [28].
The 4-Square Step Test (4SST), a valid, reliable and
sensitive clinical tool was used to assess dynamic stepping
balance and rapid changes in direction [30]. The 4SST
measures the time it takes to step over four walking sticks
placed in a four square configuration, requiring the par-
ticipant to step over and clear a height of 2.5 cm in all
directions following previously documented protocols
[30]. Although this test is not routinely used for children
with CP, it was included because of its use to predict falls
in people with neurological impairments. A score of
15 seconds or more has been shown to be the cut-off
point to identify falls risk in people with neurological
impairments [30].
Self reported incidence of toe drag and falls was mea-
sured using a questionnaire from our pilot study [23].
The questions asked were “How often do you drag your
toes when you are walking?” and “How often do you
fall over?” Answers were given on a five point ordinal
scale (0–4), with a higher score indicating an increased
incidence.
Range of motion and spasticity
Goniometry measures of passive and dynamic (Modified
Tardieu Scale) ankle dorsiflexion in subtalar neutral (with
the knee extended) and popliteal angle in supine were
taken by DP following previously documented protocols
[23, 31]. A change in angle by 10 degrees was considered
clinically meaningful [32]. The Australian Spasticity As-
sessment Scale (ASAS), a five point ordinal scale was done
concurrently to measure spasticity for gastrocnemius and
hamstrings because of its proven validity and reliability in
documenting spasticity in clinical practice [33]. We consid-
ered that a score change of one was clinically meaningful.
FES intervention
Participants in the FES group received the FES device
after the baseline assessment. The Walk Aide® (In-
novative Neurotronics, Austin, TX, USA) is a small
(8.2 cm × 6.1 cm × 2.1 cm, 87.9 g) device that delivers
asymmetrical biphasic surface electrical stimulation
(ES) in a synchronized manner to stimulate the motor
neurons of the tibialis anterior muscle, which dorsi-
flexes the ankle during the swing phase of gait. It is at-
tached to the participant’s leg by a cuff that sits just
under the knee on the affected side. One electrode
was placed on the muscle belly of tibialis anterior and
the other on the common peroneal nerve, which in-
nervates tibialis anterior and other ankle dorsiflexors
(extensor digitorum longus, peroneus tertius and ex-
tensor hallucis longus). During a gait cycle, the Walk
Aide® is triggered by an individualized program detect-
ing changes in tibia angle to stimulate ankle
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dorsiflexion. Specific attention and time was spent by
DP to ensure appropriate electrode placement and
pulse width settings for accurate ankle dorsiflexion
without excessive and unwanted movements of the
foot. The set up procedure followed that described in
our pilot study [23]. Participants and parents were
supported so that they were confident and independ-
ent with the FES device, ensuring balanced dorsiflex-
ion (no excessive subtalar eversion) with every use.
Weekly to fortnightly visits at home or school were
necessary to support daily FES use. This included
training parents, teachers and education assistants on
the use of the device as well as conducting classroom
talks so that the participant’s peers were aware of what
the device was and why it was being worn. These visits
also enabled electrode placement and integrity checks
and inspection for any adverse events.
Participants were asked to use the FES device for at least
four hours per day, six days per week during the eight-
week treatment period. This was monitored through the
usage log on the device itself. To enable participants an
opportunity to accommodate to the device, they were
asked to build up gradually to the required dosage over
the first week.
Participants in the FES intervention group did not
wear their AFO throughout the study period. They were
all provided with customized in-shoe orthoses at the
commencement of the study to support foot posture and
account for leg length discrepancies particularly in the
absence of AFOs. Participants in the control group were
asked to continue with their usual orthotic protocol.
Statistical analysis
Based on effect sizes observed in our pilot study of FES
use [23], a one tailed alpha of 0.05 and power of 80 %
power analysis suggested that each group required at least
15 participants per group to detect a clinically meaningful
change in functional muscle strength (by six heel raises).
Normality was established for all clinical and gait mea-
sures through examining distributional plots, Q-plots and
the Shapiro-Wilk test. Means and standard deviations
were reported for each group for each phase. Determining
between group differences was the main focus and this
was examined using repeated measures ANCOVA (using
the baseline as the covariate) to account for the correl-
ation between repeated measures over time. Tukey’s
post-hoc analysis was applied if a significant main ef-
fect for group and time or an interaction of these was
found enabling appropriate adjustments for the mul-
tiple comparisons and calculation of mean differences
and 95 % confidence intervals. To better understand
the significance of the statistically significant compari-
sons for the gait data, effect sizes were also determined
by using Cohen’s d calculation with a value of 0.8
considered a large effect, 0.5 to be a medium and 0.2 to be
a small effect [34]. Assumptions for the ANCOVA were
examined and met. Actigraphy® was only measured at
baseline and post treatment and so was examined using
an independent t-test. The Mann–Whitney U test was
used to determine between group differences for or-
dinal scales of ASAS and self-reported toe-drag and
falls with medians and interquartile ranges reported for
each group in each phase. Statistical significance was
accepted as p < 0.05. All statistical analyses were per-
formed using STATA version 12.1 (TestCorp, Texas).
Results
Thirty-two children, mean age 10 y 8 mo (SD 3y 3mo)
with USCP GMFCS I or II, were recruited for the study.
Baseline participant characteristics are shown in Table 2.
All participants had spasticity in the lower limb, three
participants had mixed tone with spasticity and dystonia
(as indicated by the Hypertonia Assessment Tool) [35].
All participants who attended the initial appointment
completed the study. There was no missing clinical data
in the study, with all 32 participants assessed at all three-
time points in their original group allocation.
There were no clinically significant differences in the
primary outcome measures between the groups at base-
line (baseline values provided in Tables 3 and 4). Acti-
graphy® data was returned in all but one participant at
baseline. There were no significant differences in MVPA
between the groups at baseline (p = 0.428) and post treat-
ment (p = 0.931).






Weight (kg) 38.5 (15.2) 37.4 (15.9)
Gender Male: 9 Male: 8
Female: 7 Female: 8
Side of hemiplegia Right: 11 Right: 12
Left: 5 Left: 4
GMFCS I: 10 I: 10






Winters Gage and Hicks I: 0 I: 1
II: 16 II: 15
Clinical measures
Gastrocnemius ASAS 2 (1.5-3) 2 (1.5-3) 1.00a
Passive Dorsiflexion (°)
(knee extended)
11.94 (5.87) 10.5 (5.54) 0.482b
aMann Whitney U test; bt test; GMFCS Gross Motor Function Classification
System, AFO Ankle Foot orthoses, ASAS Australian Spasticity Assessment Scale
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All participants had the FES device set with a frequency
of 33Hz with pulse width ranging from 25 to 100 μs. Par-
ticipants used the FES for a mean daily use of 6.2 (SD 3.2)
hours over the eight-week intervention period. There were
no reported unintended effects or adverse events.
Gait measures
At the post treatment assessment, the groups were sig-
nificantly different (with small to medium effect sizes)
when the treatment group was wearing the FES device
(Table 4). With the FES device on at post treatment, the
treatment group had an increased ankle angle at initial
contact (mean difference 11.9°, 95 % CI 6.8° to 17.1°;
p < 0.001; d = 0.6), increased ankle angle in maximum
dorsiflexion in swing (mean difference 8.1°, 95 % CI
1.8 to 14.4°; p = 0.007; d = 0.4), increased normalized
time in stance (mean difference 0.27, 95 % CI 0.05 to
0.49; p = 0.011; d = 0.4) and increased normalized step
length on the affected side (mean difference 0.06,
95 % CI 0.003 to 0.126; p = 0.035; d = 0.4) when com-
pared to the control group. Without the FES device
on at post treatment, the treatment group continued
to demonstrate increased normalized time in stance (mean
difference 0.23, 95 % CI −0.001 to 0.47; p = 0.050; d = 0.4)
when compared to the control group and this was consid-
ered a small/medium effect size. There were no other sig-
nificant differences between the groups for the
remaining ankle kinematic and temporal spatial gait
measures at post treatment and at follow-up.
Activity clinical measures
The CBMS scores were significantly different between
the groups with the treatment group demonstrating
higher scores both at post treatment, (mean difference
8.3 units, 95 % CI 3.2 to 13.4 units; p < 0.001) and at
follow-up (mean difference 8.9 units, CI 3.8 to 13.9
units; p < 0.001). After the FES treatment, the treatment
group had a significant reduction in the incidence of self-
reported toe drag (p = 0.002) and a significant reduction in
self-reported falls at follow-up (p = 0.022) when compared
to the control group.
Spasticity and range of movement
There were significant differences between the groups
for gastrocnemius spasticity with the median score in
the treatment group decreasing from ASAS 2 at base-
line to ASAS 1 post treatment (p = 0.038). The groups
were also significantly different at follow-up, with the
treatment group having increased dynamic ankle dorsi-
flexion range (mean difference 6.9°, 95 % CI 0.4° to
13.6°; p = 0.035). There were no significant differences
between the groups for passive dorsiflexion and popliteal
angle range of movement post treatment and at follow-up
(Additional file 1). Notably, there was no mean loss of ankle
Table 3 Mean (SD) of groups and corresponding mean difference between groups (95 % CI) reported for spasticity and activity
clinical measures at baseline (A), post treatment (B) and follow-up (C)
FES Control Mean difference (95 % CI) Between group p value
ASAS gastrocnemiusa A 2 (1.5-3) 2 (1.5-3)
B 1 (0.5-2) 2 (2–2) - p = 0.038b
C 2 (0.5-3) 2 (2–3) - p = 0.090
Dynamic dorsiflexion ROM (°) A 0 (10.7) 1.1 (8.8)
B 5.9 (9.4) 1.9 (7.1) 4.7 (−1.9 to 11.3) p = 0.245
C 4.5 (9.8) −1.8 (10.9) 6.9 (0.4 to 13.6) p = 0.035b
4SST (seconds) A 10.9 (2.8) 10.6 (3.3)
B 9.0 (2.6) 9.6 (2.1) −0.1 (−0.2 to 0.03) p = 0.182
C 8.5 (2.8) 9.1 (2.6) −0.1 (−0.3 to 0.03) p = 0.160
Self-report toe draga A 2 (1.5-4) 4 (2–5)
B 2 (1–3) 4 (2.5-5) - p = 0.002b
C 2 (1–3.5) 4 (2–4) - p = 0.069
CMBS (score out of 96) A 56.4 (14.8) 53.5 (16.5)
B 67.7 (12.8) 56.9 (16.9) 8.3 (3.2 to 13.4) p < 0.001b
C 70.4 (11.3) 58.9 (16.2) 8.9 (3.8 to 13.9) p < 0.001b
Self-report fallsa A 2 (1–3) 3 (2–4)
B 2 (1–2.5) 2 (2–3) - p = 0.089
C 1.5 (1–2) 2.5 (2–3.5) - p = 0.011b
ASAS Australian Spasticity Assessment Scale, ROM Range of Motion, 4SST Four Square Step Test, aMann Whitney U tests with reported medians and IQR;
bSignificant difference between the groups p < 0.05; − Calculation and test not indicated; CBMS Community Balance Mobility Scale
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or knee range of motion at both assessment time points in
the treatment group.
Discussion
Supporting our first hypothesis, this study documents
evidence of an FES orthotic effect in gait with improve-
ments in ankle kinematics to enable toe clearance when
walking. The improvement in ankle kinematics further
strengthens the current literature supporting the use of
FES to the ankle dorsiflexors in children with USCP, to
increase the ankle angle in swing to functionally reduce
toe drag when walking [18, 22, 36, 37]. The improve-
ment in the time spent in stance on the affected leg pro-
vides further evidence that FES in swing can also affect
some stance phase features. Once again this strengthens
previous results where this effect has also been reported,
but only in three children with CP [18]. Hence FES
seems to offer some limited but similar features to
AFOs, in terms of its effectiveness in improving ankle
kinematics, time spent in stance and step length [11–13].
For children who do not require the stance phase knee
and hip control that is offered by AFOs, clinicians may
consider the implementation of FES for children with
USCP that exhibit equinus gait patterns.
Supporting our second hypothesis, after eight-weeks of
FES, and with the removal of the FES device, participants
in the treatment group demonstrated a therapeutic effect
with significantly better CBMS scores, reduced gastrocne-
mius spasticity and self-reported toe drag compared to the
control group. There has been limited evidence supporting
the therapeutic effect in CP and this has largely been at-
tributed to variable intervention parameters with different
length and setting of intervention, different target muscles
for stimulation and underpowered sample sizes to de-
tect significant differences [37–41]. However, the com-
pelling evidence supporting the therapeutic effect in
the adult post stroke population, where FES is also used
for drop foot has been largely attributed to the applica-
tion of FES in functional contexts [42]. Therefore the
results from the current study support the implementa-
tion of daily community applied FES, as this appears to
be a necessary component particularly if the goal is to
achieve a therapeutic effect.
The mechanism for the therapeutic effect observed at
post treatment is unclear. We reason that the reduced
gastrocnemius spasticity, improvement in time in stance
and community mobility and balance skills reflect more
co-ordinated muscle activation at the ankle joint. Referred
Table 4 Mean (SD) of groups and corresponding mean difference between groups (95 % CI) reported for gait kinematics and
temporal-spatial parameters at baseline (A), post treatment (B) and follow-up (C)
Group Mean Difference between groups (95 % CI)
A B C B B C
Outcome Rx Con Rx Rx Con Rx Con Rx FES - Con Rx No FES - Con Rx No FES - Con
No FES FES No FES No FES
Initial contact ankle angle (°) −7.8 −5.5 3.2 −5.1 −7.6 −6.1 −6.6 11.9 - -
(6.7) (8.2) (6.1) (7.9) (8.2) (7.8) (8.1) (6.8 to 17.1)*
Max. DF stance (°) 12.9 13.8 15 14.8 12.9 13 12.0 - - -
(5.7) (7.6) (4.5) (4.4) (6.6) (4.9) (7.3)
Max. DF swing (°) −6.1 −4.6 3.4 −3.3 −3.8 −2.1 −4 8.1 - -
(9.5) (9.5) (9.6) (6.9) (8.0) (8.4) (7.6) (1.8 to 14.4)*
Toe-off ankle angle (°) −7.9 −14.2 −11.2 −15.7 −16.2 −16.8 −16.2 - - -
(12.5) (13.1) (9.9) (8.9) (8.8) (9.2) (12.1)
Time in stancea 2.1 2.2 2.3 2.3 2.1 2.2 2.1 0.27 0.23 -
(0.3) (0.3) (0.3) (0.3) (0.2) (0.2) (0.3) (0.05 to 0.49)* (−0.001 to 0.47)*
Step length – hemia 0.4 0.4 0.5 0.5 0.4 0.5 0.5 0.06 - -
(0.1) (0.1) (0.1) (0.1) (0.1) (0.1) (0.1) (0.003 to 0.126)*
Step length- non hemia 0.5 0.5 0.5 0.5 0.5 0.5 0.5 - - -
(0.1) (0.1) (0.1) (0.1) (0.1) (0.1) (0.1)
Ankle velocity before
initial contacta
0.4 0.5 0.5 0.5 0.5 0.5 0.5 - - -
(0.1) (0.2) (0.1) (0.2) (0.1) (0.1) (0.1)
Walking velocity (m/s) 1.2 1.2 1.2 1.1 1.2 1.2 1.2 0.04 −0.04 −0.04
(0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.2) (0.09 to −0.12) (−0.10 to 0.11) (−0.09 to 0.02)
Rx treatment group, Con control group, FES Functional Electrical Stimulation, −, Calculation and test not indicated; aValues reported are normalized dimensionless
values; *p <0.05
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to as muscle co-contraction due to impaired reciprocal in-
hibition that is often observed at the ankle during gait, [43]
can be used as a strategy to improve joint stability [44].
However it may also be functionally detrimental by impair-
ing co-ordinated muscle activation consequently impacting
balance control to result in asymmetrical gait patterns [45].
Stimulation to the ankle dorsiflexors may address problems
with reciprocal inhibition due to the repetitive nature of
the intervention by moving the ankle in and out of dorsi-
flexion with each step [18, 43]. In effect, this would enable
more balanced muscle function at the ankle, improving
stability thus accounting for the improvement in commu-
nity mobility and balance scores.
The continued therapeutic effect in community mobil-
ity and balance skills noted at follow-up supports our
pilot study results [23]. These changes provide some evi-
dence to suggest the role of motor learning with the de-
velopment of secondary repertoires of movement. This
could be because the participants’ ambulation needs
were challenged as they no longer had the orthotic ben-
efits of FES or an AFO. Further work to substantiate
the possibility of neuroplastic changes is therefore war-
ranted in future studies. The evidence for supporting
the therapeutic effect particularly regarding community
mobility and balance skills is functionally important as
it means that these changes are possible with minimal
therapy face time, a significant consideration in com-
munity clinical practice.
There were no ankle kinematic gait therapeutic ef-
fects, suggesting that orthotic effects, as with AFOs, are
use-dependent. We speculate that the absence of ankle
kinematic therapeutic effects could be attributable to
inadequate length or dosage of treatment. However, it
could also be attributable to inadequate elicitation of the
central nervous system from the FES settings as higher
frequencies were not available, whilst higher pulse widths
only resulted in discomfort and unwanted excessive move-
ments into ankle eversion [46]. Contrary to previous re-
ports, there were no significant improvements in passive
ankle dorsiflexion range of motion [47]. It is worth noting
that there was no significant loss in range of motion ei-
ther. This is an important finding because it demonstrates
that the removal of an AFO for a short period of FES will
not detrimentally affect ankle range of motion for children
in this age group. However, it should be noted that partici-
pants in this study did not have high levels of spasticity at
baseline, hence these results are limited to children with a
Winters Gage and Hicks classification of I and II with a
gastrocnemius ASAS of no more than three.
Literature supporting the use of AFOs to maintain or
even improve ankle range of motion has methodological
limitations such as difficulties with standardization of
materials and limitations in the outcome measures used.
However, it continues to be acceptable in current clinical
practice because it is coupled with clinical expertise and
assessment [7, 12]. Certainly wearing AFOs or even using
FES does not replace the need for vigorous range of move-
ment monitoring, pharmacological or orthopaedic inter-
ventions. Individual assessments continue to be necessary
when considering and applying FES for the orthotic and
therapeutic effects. Specifically, clinicians will need to
evaluate the effectiveness of dorsiflexion stimulation with-
out exacerbating any pre-existing foot deformities as well
as to ensure the lower limb biomechanical requirements
are met before applying FES in gait i.e. able to meet the in-
clusion criteria specified for this study. The role of com-
munity therapy is highlighted here to ensure that FES is
used appropriately at home, school and community.
Whilst the results do support both the orthotic and
therapeutic effects of FES in a randomised controlled
trial, there are some study limitations to note. Gait analysis
was performed using two-dimensional video for easy repli-
cation in the community. The reliability of using software
for sagittal plane measurements has been established [48]
and our results match previous ankle kinematic measures
obtained from three-dimensional analysis [22]. This
procedure was also enhanced with force platforms to
accurately determine significant gait events. However,
three-dimensional analyses would have offered gait kinetic
information. Also, it was not possible to blind the assessor
either during the clinical assessments or during the gait
video analysis due to observable facial identify and the pres-
ence of a Walk Aide® visibly attached to the leg. To our
knowledge, there are no valid measures of toe drag and falls
for this population. We therefore developed our own ques-
tionnaire for this study, which was used in our pilot study,
but has not been validated. There was some missing Acti-
graph® data and this may have influenced the results. Due
to limited number of Actigraph® devices available, follow-
up assessments were not possible. Inclusion of this data for
the follow-up assessment time point would have strength-
ened the study to confirm that the therapeutic effect was
due to the residual effect of FES and not due to increased
levels of MVPA. Another limitation is that although a sta-
tistically significant difference in dynamic ankle dorsiflexion
range was determined between groups, the mean change
did not exceed the variability in measurement at the joint
[32]. Finally, many variables were explored here over several
time points and this may be a limitation because of the po-
tential for Type I error. The strength of this study however
is the high compliance, with no missing data or drop-outs.
This reflects the acceptability of the intervention as well as
the efficacy and potential for this intervention to be imple-
mented in community clinical practice.
Conclusion
Short-term daily community FES is an effective activity
based treatment with both orthotic and therapeutic
Pool et al. BMC Pediatrics  (2015) 15:154 Page 8 of 10
effects. The improvements in community mobility and
balance skills and spasticity are evident for up to six
weeks post treatment. This suggests that FES applied
during everyday walking activities is a viable treat-
ment option for children with USCP and equinus gait
patterns.
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